MannKind Corporation to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum

  MannKind Corporation to Present at Canaccord Genuity Medical Technologies &
  Diagnostics Forum

Canaccord Genuity Medical Technology & Diagnostics Forum 2013

Business Wire

VALENCIA, Calif. -- November 7, 2013

MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and
commercializing treatments for diabetes, announced today that it will present
at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday,
November 14, 2013 at 11:30 AM (ET) at the Westin Grand Central in New York
City.

Interested parties can access a link to the live webcast of the presentations
from the News & Events section of the Company's website
athttp://www.mannkindcorp.com.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and
commercialization of therapeutic products for patients with diseases such as
diabetes. Its lead product candidate, AFREZZA®, has completed Phase 3 clinical
trials. MannKind maintains a website at www.mannkindcorp.com to which MannKind
regularly posts copies of its press releases as well as additional information
about MannKind. Interested persons can subscribe on the MannKind website to
e-mail alerts that are sent automatically when MannKind issues press releases,
files its reports with the Securities and Exchange Commission or posts certain
other information to the website.

Contact:

MannKind Corporation
Matthew Pfeffer
Chief Financial Officer
(661) 775-5300
mpfeffer@mannkindcorp.com
 
Press spacebar to pause and continue. Press esc to stop.